IMMUNOGEN INC
BiotechIMMUNOGEN INC is a biotechnology company focused on Oncology.
FDA Novel Drug Designations
(2022)See 1 novel approval →
IMMUNOGEN INC at a Glance
- Strong track record with 88% execution quality across 11 trials
IMMUNOGEN INC's Key Drugs
IMMUNOGEN INC's core commercial portfolio centers on ELAHERE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
IMMUNOGEN INC's Recent FDA Approvals
New NDA/BLA approvals for IMMUNOGEN INC over the last two years — novel drugs only, excluding generics and label supplements.
IMMUNOGEN INC's Therapeutic Areas
IMMUNOGEN INC's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IMMUNOGEN INC's Top Competitors
IMMUNOGEN INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IMMUNOGEN INC Pipeline Snapshot
IMMUNOGEN INC has 11 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 0 Phase 2 and 9 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/2 completed
- • Speed: 55 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2022-11-14
- Latest
- 2025-07-14
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges